A United States study has revealed new insights into how the eye handles inflammation, particularly in autoimmune uveitis.
New clinical data from Polyactiva’s Phase 2 clinical trial (LATA-CS102) demonstrates that its novel glaucoma treatment technology, PA5108, met its efficacy and safety endpoints.
Cura Day Hospitals has announced it will acquire PresMed Holdings, creating a network of 36 facilities across Australia.
The University of Western Australia (UWA) has expanded its hub and spoke eye care model with the establishment of a new comprehensive eye health
DISCLAIMER : THIS WEBSITE IS INTENDED FOR USE BY HEALTHCARE PROFESSIONALS ONLY.
By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.
